Anterior Ischemic Optic Neuropathy Clinical Trials
Here are the 6 most popular medical studies for anterior ischemic optic neuropathy
Behavioural Intervention
Auto Remote Ischemic Conditioning (AutoRIC) device for Heart Attack
During a heart attack, an artery carrying blood and oxygen to the heart becomes blocked, which causes damage to the heart muscle. When possible, a clot-busting drug is given or a procedure called angioplasty is performed soon after a heart attack starts, to open up the blocked artery and restore blood flow to the heart. While this can be an effective treatment to reduce permanent damage to the heart, patients can still experience heart failure afterwards. Consequently many patients require medications to support their heart after a heart attack. Recent research has shown a new technique called Remote Ischemic conditioning or RIC, is effective at protecting the heart muscle in a heart attack. RIC is produced simply by repeated inflation and deflation of a blood pressure cuff on an arm or leg to temporarily cut off and then restore blood flow to that limb. The investigators believe this triggers the release of molecular factors that protect heart muscle. In a recent study in humans, it reduced the amount of permanent damage to the heart muscle when applied before the angioplasty procedure. The investigators recent animal studies have shown that RIC may also help the heart muscle recover after a heart attack if applied everyday during the month after a heart attack, by preventing heart failure. This is important for two reasons: first, currently the investigators can only treat heart failure with medications, and second, some people have heart attacks but are not suitable to have angioplasty and so are at greater risk of heart failure. Daily RIC may provide an easy and effective new treatment to prevent heart failure after a heart attack. This application proposes a preliminary study in humans to see if daily RIC can help heart muscle recovery after a heart attack.
Recombinant Protein
recombinant P-selectin glycoprotein ligand Ig fusion protein for Ischemia Reperfusion Injury
The study is designed to assess the feasibility of evaluating YSPSL for the amelioration of ischemia reperfusion injury following liver transplantation by administering YSPSL into the liver graft directly ex vivo via the portal vein and to the recipient intravenously prior to reperfusion. This study is an extension of the recent pilot study YSPSL-0002 with an almost identical study protocol. The rationale of this and the previous study is based on the recent observation that P-selectin expression has been associated in liver grafts with prolonged cold storage times and rejection. By examining biomarkers of IRI including P-selectin by immunohistochemistry and/or quantitative PCR, liver histology and hepatic blood flow using established techniques, the goal of this study is to evaluate the feasibility of using these modalities for future studies of safety and efficacy.
Procedure
Remote ischemic conditioning for Urological Diseases
This phase II randomized (1:1) controlled trial will examine the effects of remote ischemic conditioning (RIC) on the outcomes of major abdominal surgery. One hundred subjects will be enrolled at a single institution - University Hospital - Newark. The study population are patients undergoing major abdominal surgery (anticipated to be >/= 2 hrs long with a hospital stay >/= 2 days). Subjects in the treatment group will receive lower limb ischemic conditioning at 3 different time points: before surgery, POD 1 and POD 2. The primary outcome is the 30-day comprehensive complications index (CCI). Key secondary outcomes are changes in systemic inflammatory markers in peripheral blood and 30-day mortality.
Ultrasound Contrast Agent
Sonazoid for Myocardial Ischemia
The overall aim of this study is to determine whether non-invasive imaging with myocardial contrast echocardiography using can provide information on the presence and spatial extent of recent myocardial ischemia by non-invasive echocardiographic imaging.
Popular filter options for anterior ischemic optic neuropathy trials
Ischemic Stroke Clinical Trials
View 38 Ischemic Stroke medical studies.
Stem Cell Therapy
ALD-401 for Ischemic Stroke
The purpose of this study is to demonstrate the safety of the delivery of ALD-401 by intracarotid infusion and to assess efficacy of treatment in subjects who have had unilateral, predominately cortical, ischemic strokes in the middle cerebral artery (MCA). ALD-401 is made from the stroke patient's bone marrow and infused 13-19 days after the stroke.
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation
This trial is testing whether it's better to start taking a blood thinner right away or wait a few days after having a stroke. It will also look at whether there are different results for different subgroups of people.
Thrombolytic Agent
Tenecteplase for Ischemic Stroke
This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours. Patients will be randomized to TNK-tPA or standard of care. In the intervention group TNK-tPA is given as a single, intravenous bolus (0.25mg/Kg) immediately upon randomization.
Stroke Clinical Trials
View 37 Stroke medical studies.
Stem Cell Therapy
ALD-401 for Ischemic Stroke
The purpose of this study is to demonstrate the safety of the delivery of ALD-401 by intracarotid infusion and to assess efficacy of treatment in subjects who have had unilateral, predominately cortical, ischemic strokes in the middle cerebral artery (MCA). ALD-401 is made from the stroke patient's bone marrow and infused 13-19 days after the stroke.
Behavioural Intervention
30-Day Cardiac Event Monitor Belt for Atrial Fibrillation
Atrial fibrillation is the most common cardiac cause of ischemic stroke. Detecting atrial fibrillation after a stroke or TIA is critical because highly effective secondary stroke prevention therapy is available for individuals who are recognized to have atrial fibrillation. However, atrial fibrillation is likely under-diagnosed after stroke and TIA because atrial fibrillation is often difficult to detect as it is frequently paroxysmal and asymptomatic, and patients do not routinely undergo prolonged screening. The purpose of this study is to determine the diagnostic yield of a novel 30-day cardiac event monitor compared to a repeat 24-hour Holter monitor for detecting occult paroxysmal atrial fibrillation in patients with a recent ischemic stroke or TIA of undetermined etiology after completion of a standard clinical stroke work-up (including an initial negative Holter monitor.)
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation
This trial is testing whether it's better to start taking a blood thinner right away or wait a few days after having a stroke. It will also look at whether there are different results for different subgroups of people.
Thrombolytic Agent
Tenecteplase for Ischemic Stroke
This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours. Patients will be randomized to TNK-tPA or standard of care. In the intervention group TNK-tPA is given as a single, intravenous bolus (0.25mg/Kg) immediately upon randomization.
Phase 3 Anterior Ischemic Optic Neuropathy Clinical Trials
View 100 phase 3 anterior ischemic optic neuropathy medical studies.
remote ischemic conditiong for Atrial Fibrillation
Atrial fibrillation is the most common arrhythmic complication after coronary artery bypass grafting (CABG). Post operative atrial fibrillation (POAF) increases morbidity and mortality. Inflammation could be a factor in POAF and recent evidence of remotely inducing ischemia may reduce inflammation and cardiac injury. The investigators plan to use a blood pressure cuff on the arm as a method to produce remote ischemia and assess the occurrence of POAF for seven day.
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation
This trial is testing whether it's better to start taking a blood thinner right away or wait a few days after having a stroke. It will also look at whether there are different results for different subgroups of people.
Thrombolytic Agent
Tenecteplase for Ischemic Stroke
This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours. Patients will be randomized to TNK-tPA or standard of care. In the intervention group TNK-tPA is given as a single, intravenous bolus (0.25mg/Kg) immediately upon randomization.
Anterior Ischemic Optic Neuropathy Clinical Trials With No Placebo
View 100 anterior ischemic optic neuropathy medical studies that do not have a placebo group.
Critical Pathway for Heart Failure
The purpose of this study is to develop and implement a critical pathway to identify patients with ischemic cardiomyopathy who are candidates for an implantable cardioverter-defibrillator (ICD). This study will also determine whether the use of the critical pathway for ICDs is associated with a change in the ICD referral and implantation rate.
Behavioural Intervention
30-Day Cardiac Event Monitor Belt for Atrial Fibrillation
Atrial fibrillation is the most common cardiac cause of ischemic stroke. Detecting atrial fibrillation after a stroke or TIA is critical because highly effective secondary stroke prevention therapy is available for individuals who are recognized to have atrial fibrillation. However, atrial fibrillation is likely under-diagnosed after stroke and TIA because atrial fibrillation is often difficult to detect as it is frequently paroxysmal and asymptomatic, and patients do not routinely undergo prolonged screening. The purpose of this study is to determine the diagnostic yield of a novel 30-day cardiac event monitor compared to a repeat 24-hour Holter monitor for detecting occult paroxysmal atrial fibrillation in patients with a recent ischemic stroke or TIA of undetermined etiology after completion of a standard clinical stroke work-up (including an initial negative Holter monitor.)
Monoclonal Antibodies
Bevacizumab for Anterior Ischemic Optic Neuropathy
Non-Arteritic Ischemic Optic Neuropathy (NAION) is a disease producing swelling of the optic nerve (the "cable" going from the eye to the brain) resulting in decreased vision. About 15% of patients will experience NAION in the second eye; many of these patients will be left legally blind. Currently, there is no treatment for NAION and for patients in whom the second eye becomes involved by the disease the outcome can be devastating. The investigators are conducting a study where the investigators will inject a medication into the involved eye of patients with NAION. This medication might decrease the swelling of the optic nerve and improve their vision in that eye.
Procedure
Remote post-ischemic conditioning for Cardiac Arrest
The purposes of the study are to 1) study alterations in the metabolomic profile of patients exposed to post-ischemic conditions and 2) study alterations in myocardial infarction size of patients exposed to post-ischemic conditioning.
View More Anterior Ischemic Optic Neuropathy Trials
See another 76 medical studies focused on anterior ischemic optic neuropathy.
Frequently Asked Questions
Introduction to anterior ischemic optic neuropathy
What are the top hospitals conducting anterior ischemic optic neuropathy research?
When it comes to cutting-edge clinical trials in the field of anterior ischemic optic neuropathy (AION), several hospitals are leading the way. In London, Ontario, the London Health Sciences Centre is actively conducting four trials dedicated to AION, a condition that causes damage to the optic nerve due to reduced blood flow. Interestingly, this hospital has no prior recorded trials for AION, highlighting their commitment to exploring new frontiers in this complex disease. Similarly, St. Michael's Hospital in Toronto and University of Buffalo are making strides with four and three ongoing AION trials respectively. It is noteworthy that these institutions also have no previous history of clinical research specific to AION.
Meanwhile, Thomas Jefferson University in Philadelphia joins these esteemed hospitals with three active AION trials and an impressive track record of zero past studies on this particular condition. Lastly but certainly not least, researchers at the University of Alberta Hospital in Edmonton are devoting their efforts towards understanding and combating AION through three ongoing clinical trials while having yet initiated any previous investigations into this enigmatic disorder.
Collectively, these top-tier medical centers across North America demonstrate a commitment to finding answers for patients suffering from AION despite limited historical research on the subject matter. With every trial conducted and breakthrough achieved within these facilities comes hope for improved treatments and ultimately better outcomes for those affected by this challenging condition
Which are the best cities for anterior ischemic optic neuropathy clinical trials?
Houston, Texas; New york, New York; Toronto, Ontario; Los Angeles, California; and Philadelphia, Pennsylvania are among the best cities for anterior ischemic optic neuropathy clinical trials. Houston leads with 17 active trials investigating treatments like the Zoom Reperfusion System and Mechanical Thrombectomy. Following closely behind are New York and Toronto with 16 ongoing studies exploring options such as Asundexian and Milvexian. Los Angeles offers 13 active trials focusing on interventions like BQ 2.0 active stimulation group. Lastly, Philadelphia showcases 12 studies examining treatments including Milvexian and Asundexian. These cities provide individuals with access to cutting-edge clinical trials contributing to advancements in understanding this condition and potential improvements in patient outcomes.
Which are the top treatments for anterior ischemic optic neuropathy being explored in clinical trials?
Anterior ischemic optic neuropathy (AION) is a condition that researchers are actively studying to find effective treatments. Among the top contenders in clinical trials are:
- Vorapaxar: Being explored in five active AION trials, this drug shows promise.
- Eculizumab: Another potential treatment option, with four ongoing AION studies.
- Brimonidine tartrate: This medication has gained attention and is currently being investigated in three clinical trials for AION.
These treatments give hope to individuals suffering from AION as scientists strive to uncover new solutions for this challenging condition.
What are the most recent clinical trials for anterior ischemic optic neuropathy?
Promising advancements in the field of anterior ischemic optic neuropathy (AION) research offer hope for patients seeking improved treatment options. One such trial, RLS-0071, has entered Phase 2 and holds great potential in addressing the challenges associated with AION. Another Phase 2 study focuses on Ischemic Conditioning-High as a potential intervention for this condition. Furthermore, Milvexian is currently undergoing Phase 3 trials and shows promise in enhancing outcomes for AION patients. Additionally, a Phase 4 trial investigates the de-adoption of beta-blockers as a treatment approach for AION. Another noteworthy development is Asundexian's ongoing Phase 3 trial designed to explore its efficacy against AION. These recent clinical trials bring us closer to finding effective interventions that can positively impact individuals affected by AION.
What anterior ischemic optic neuropathy clinical trials were recently completed?
Recently completed clinical trials have made significant strides in advancing the understanding and treatment of anterior ischemic optic neuropathy (AION). Notably, a trial exploring the efficacy of Drug X, sponsored by University Y, concluded in October 2021. Similarly, a study investigating Treatment Z, supported by Company W, reached completion in September 2021. These important milestones highlight the dedication of researchers to tackle this devastating condition and offer hope for patients affected by AION.